Mediwound is a global leader in next-generation enzymatic therapeutics, specializing in non-surgical tissue repair. They are dedicated to improving patient experiences and outcomes while reducing costs and unnecessary surgeries. One of their flagship products is NexoBrid, a specialized gel that effectively removes burn eschar within four hours, without harming surrounding viable tissue.

NexoBrid is currently available in the United States, European Union, Japan, India, and other international markets. Supported by the US Biomedical Advanced Research and Development Authority, its development is backed by the US Department of Health and Human Services. Mediwound is also developing EscharEx, a biologic designed for the debridement of chronic and hard-to-heal wounds.

Phase 2 studies have shown that EscharEx is highly effective and significantly faster than standard-of-care treatments, with a strong safety profile. Additionally, Mediwound is working on MW005, a topical biological drug for low-risk Basal Cell Carcinoma. Phase I/II clinical trials have shown promising results, demonstrating that MW005 is a safe and effective treatment option.

At Mediwound, their culture promotes care, innovation, delivery, and continuous learning. They invest in their employees' personal and professional development, push scientific boundaries, and deliver exceptional service to prioritize customer satisfaction and improved patient outcomes. Join Mediwound's team of motivated and talented scientists to contribute to their mission of elevating the standard of care and revolutionizing patient experiences